NovaBridge Biosciences Q2 FY2023 earnings call

• Raj Kannan outlined strategic pillars: rapidly advance two oncology clinical assets globally, maintain strong balance sheet, and establish a US-based global biotech operating model. - John Hayslip provided clinical updates: uliledlimab showed encouraging Phase 1b/2 results in non-small cell lung cancer, givastomig has potential in gastric cancer with ongoing trials, eftansomatropin alfa had positive Phase 3 results for growth hormone deficiency, felzartamab is in development for multiple myeloma, and lemzoparlimab is in Phase 3 for MDS.

For the first six months of 2023, total revenue was $2.7 million compared to $7.7 million in the same period of 2022. Research and development expenses were $61.6 million in 2023 vs $67.6 million in 2022, primarily due to reduced payroll and share-based compensation expenses. Administrative expenses were $33.8 million in 2023 vs $54.1 million in 2022, mainly due to lower payroll and professional services expenses.

• Plan to rapidly advance uliledlimab and givastomig into initial studies in the US and beyond by the first half of 2024. - Maintain strong balance sheet by streamlining and rationalizing spend for promising programs. - Focus on establishing a US-based global biotech company with Board support.

• Risks related to clinical trial outcomes, regulatory approvals, market competition, and potential differences between expected and actual results due to unforeseen factors or evolving environments.

Q: Comment on safety profile of eftansomatropin alfa Phase 3 trial and timeline for regulatory approval and commercial launch A: John Hayslip noted favorable safety profile vs Norditropin, Andrew Zhu mentioned actively pursuing BLA submission with solid Phase 3 data foundation Q: Thoughts on givastomig capturing broader Claudin expression range and influence of magrolimab's ENHANCE trial on lemzoparlimab A: John Hayslip said givastomig may benefit broader Claudin expression, Raj Kannan stated premature to decide on lemzoparlimab until reviewing interim data and class data Q: Vision for I-Mab and timeline, commercial partnerships for pipeline A: Raj Kannan said 24-month timeline to see strategic plan progress, mentioned ongoing engagement with outside partners but premature to partner until mature data Q: Questions on CD73 antibody, design of pivotal trial, and adding chemo to CD73 therapy A: John Hayslip discussed CD73 biomarker assay and trial design, Raj Kannan and John Hayslip commented on broader patient population and potential of chemo combination Q: Questions on Claudin18.2 bispecific antibody, commercial opportunity of eftansomatropin alfa, and biology of givastomig A: Andrew Zhu and John Hayslip commented on givastomig's broad Claudin expression coverage and favorable safety, Raj Kannan said premature to comment on price of eftansomatropin alfa, John Hayslip addressed givastomig's PD effect not being a preclinical issue Q: Questions on early-stage pipeline development, CD47 projects efficacy gap and pivotal study design A: Raj Kannan discussed focus on late-stage compounds for value inflection, John Hayslip and Raj Kannan commented on CD47 project's ongoing enrollment and premature decision-making, and John Hayslip noted not commenting on uliledlimab's specific regulatory pathway until alignment with regulators